Top

Published in:

Open Access 01-12-2009 | Research

Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells

Authors: Daisuke Uchida, Tomitaro Onoue, Nasima-Mila Begum, Nobuyuki Kuribayashi, Yoshifumi Tomizuka, Tetsuya Tamatani, Hirokazu Nagai, Youji Miyamoto

Published in: Molecular Cancer | Issue 1/2009

Abstract

Background

We have demonstrated that the stromal cell-derived factor-1 (SDF-1; CXCL12)/CXCR4 system is involved in the establishment of lymph node metastasis in oral squamous cell carcinoma (SCC). Chemotherapy is a powerful tool for the treatment of oral cancer, including oral SCC; however, the effects of chemotherapeutic agents on the expression of CXCR4 are unknown. In this study, we examined the expression of CXCR4 associated with the chemotherapeutic agents in oral cancer cells.

Results

The expression of CXCR4 was examined using 3 different chemotherapeutic agents; 5-fluorouracil, cisplatin, and vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone) in B88, a line of oral cancer cells that exhibits high levels of CXCR4 and lymph node metastatic potential. Of the 3 chemotherapeutic agents that we examined, only vesnarinone downregulated the expression of CXCR4 at the mRNA as well as the protein level. Vesnarinone significantly inhibited lymph node metastasis in tumor-bearing nude mice. Moreover, vesnarinone markedly inhibited 2.7-kb human CXCR4 promoter activity, and we identified the transcription factor, Krüppel-like factor 2 (KLF2), as a novel vesnarinone-responsive molecule, which was bound to the CXCR4 promoter at positions -300 to -167 relative to the transcription start site. The forced-expression of KLF2 led to the downregulation of CXCR4 mRNA and impaired CXCR4 promoter activity. The use of siRNA against KLF2 led to an upregulation of CXCR4 mRNA.

Conclusion

These Results indicate that vesnarinone downregulates CXCR4 via the upregulation of KLF2 in oral cancer.

Available only for authorised users

Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440CrossRefPubMed

Johnson JT, Barnes EL, Myers EN, Schramm VL, Borochovitz D, Sigler BA: The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol. 1981, 107: 725-729.CrossRefPubMed

Decroix Y, Ghossein NA: Experience of the Curie Institute in treatment of cancer of the mobile tongue: II. Management of the neck nodes. Cancer. 1981, 47: 503-508. 10.1002/1097-0142(19810201)47:3<503::AID-CNCR2820470313>3.0.CO;2-1CrossRefPubMed

Johnson JT, Wagner RL, Myers EN: A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer. 1996, 77: 181-185. 10.1002/(SICI)1097-0142(19960101)77:1<181::AID-CNCR29>3.0.CO;2-0CrossRefPubMed

Labadie RF, Yarbrough WG, Weissler MC, Pillsbury HC, Mukherji SK: Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histopathologic findings. Am J Neuroradiol. 2000, 21: 310-314.PubMed

Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol. 2000, 18: 217-242. 10.1146/annurev.immunol.18.1.217CrossRefPubMed

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016CrossRefPubMed

Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR: Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res. 2001, 61: 4961-4965.PubMed

Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62: 1832-1837.PubMed

10.

Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak W, Gatzlaff P, Atzpodien J, Buer J, Lauber J: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002, 86: 1250-1256. 10.1038/sj.bjc.6600221PubMedCentralCrossRefPubMed

11.

Zhou Y, Larsen PH, Hao C, Yong VW: CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002, 277: 49481-49487. 10.1074/jbc.M206222200CrossRefPubMed

12.

Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002, 62: 6304-6311.PubMed

13.

Uchida D, Begum NM, Ammar A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H, Sato M: Possible role of stromal cell-derived factor-1/CXCR4 signaling on lymph-node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003, 290: 289-302. 10.1016/S0014-4827(03)00344-6CrossRefPubMed

14.

Uchida D, Begum NM, Tomizuka Y, Bando T, Almofti A, Yoshida H, Sato M: Acquisition of lymph node, but not distant metastatic potentials, by the over-expression of CXCR4 in human oral squamous cell carcinoma cells. Lab Invest. 2004, 84: 1538-1546. 10.1038/labinvest.3700190CrossRefPubMed

15.

Ammar A, Uchida D, Begum NM, Tomizuka Y, Iga H, Yoshida H, Sato M: The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol. 2004, 25: 65-71.

16.

Uchida D, Onoue T, Tomizuka Y, Begum NM, Miwa Y, Yoshida H, Sato M: Involvement of an autocrine stromal cell-derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res. 2007, 5 (7): 685-694. 10.1158/1541-7786.MCR-06-0368CrossRefPubMed

17.

Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996, 382: 829-833. 10.1038/382829a0CrossRefPubMed

18.

De Clercq E: The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003, 2: 581-587. 10.1038/nrd1134CrossRefPubMed

19.

Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 1997, 186: 1389-1393. 10.1084/jem.186.8.1389PubMedCentralCrossRefPubMed

20.

Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Nat Acad Sci USA. 1999, 96: 5698-5703. 10.1073/pnas.96.10.5698PubMedCentralCrossRefPubMed

21.

Moore MA: The role of chemoattraction in cancer metastases. Bioessays. 2001, 23: 674-676. 10.1002/bies.1095CrossRefPubMed

22.

Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, Sato M: Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. Br J Cancer. 1998, 77: 71-78.PubMedCentralCrossRefPubMed

23.

Sato M, Harada K, Bando T, Shirakami T, Nakashiro K, Yoshida H, Nakai S, Kawai K, Adachi M: Characteristics of antitumor activity of 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett. 1995, 91: 1-9. 10.1016/0304-3835(95)03713-7CrossRefPubMed

24.

Kawamata H, Nakashiro K, Uchida D, Hino S, Harada K, Yoshida H, Sato M: Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer. 1997, 70: 120-127. 10.1002/(SICI)1097-0215(19970106)70:1<120::AID-IJC18>3.0.CO;2-PCrossRefPubMed

25.

Guan XF, Qiu WL, He RG, Zhou XJ: Selection of adenoid cystic carcinoma cell clone highly metastatic to the lung: an experimental study. Int J Oral Maxillofac Surg. 1997, 26: 116-119. 10.1016/S0901-5027(05)80830-6CrossRefPubMed

26.

Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006, 203: 2201-2213. 10.1084/jem.20052144PubMedCentralCrossRefPubMed

27.

Asanoi H, Sasayama S, Iuchi K, Kameyama T: Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardiol. 1987, 9: 865-871.CrossRefPubMed

28.

Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998, 339: 1810-1816. 10.1056/NEJM199812173392503CrossRefPubMed

29.

Sato S, Tomoyasu S, Okabe-Kado J, Hozumi M, Tsuruoka N, Nakai S, Adachi M, Honma Y: Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol. 1996, 24: 37-42.PubMed

30.

Isaka K, Fujito A, Sagawa Y, Yudate T, Nishi H, Ito H, Takayama M: Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone). Oncol Rep. 2002, 9: 1299-1305.PubMed

31.

Khalaf W, Maina C, Byers J, Harvey W: Interferon-alpha 2β and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested. Leuk Res. 2002, 26: 169-177. 10.1016/S0145-2126(01)00100-XCrossRefPubMed

32.

Sato M, Harada K, Yura Y, Bando T, Azuma M, Kawamata H, Iga H, Yoshida H: Induction of tumour differentiation and apoptosis and LeY antigen expression in treatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis. 1997, 2: 106-113.PubMed

33.

Sato M, Harada K, Yura Y, Azuma M, Kawamata H, Iga H, Tsujimoto H, Yoshida H, Adachi M: The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma. Apoptosis. 1997, 2: 313-318. 10.1023/A:1026493205097CrossRefPubMed

34.

Patnaik A, Rowinsky EK, Tammara BK, Hidalgo M, Drengler RL, Garner AM, Siu LL, Hammond LA, Felton SA, Mallikaarjun S, Von Hoff DD, Eckhardt SG: Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. J Clin Oncol. 2000, 18: 3974-3985.PubMed

35.

Omotehara F, Kawamata H, Uchida D, Hino S, Nakashiro K, Fujimori T: Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line. Br J Cancer. 2002, 87: 1042-1046. 10.1038/sj.bjc.6600592PubMedCentralCrossRefPubMed

36.

Moriuchi M, Moriuchi H, Margolis DM, Fauci AS: USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. J Immunol. 1999, 162: 5986-5992.PubMed

37.

Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003, 278: 21631-21638. 10.1074/jbc.M300609200CrossRefPubMed

38.

Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003, 425: 307-311. 10.1038/nature01874CrossRefPubMed

39.

Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T: G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002, 3: 687-694. 10.1038/ni813CrossRefPubMed

40.

Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y: Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res. 2005, 11: 2937-2946. 10.1158/1078-0432.CCR-04-1470CrossRefPubMed

41.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL: The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 2005, 65: 10355-10362. 10.1158/0008-5472.CAN-05-0957CrossRefPubMed

42.

Manna SK, Aggarwal BB: Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis. J Immunol. 2000, 164: 5815-5825.CrossRefPubMed

43.

Anderson KP, Kern CB, Crable SC, Lingrel JB: Isolation of a gene encoding a functional zinc finger protein homologous to erythroid Krüppel-like factor: identification of a new multigene family. Mol Cell Biol. 1995, 15: 5957-5965.PubMedCentralPubMed

44.

Buckley AF, Kuo CT, Leiden JM: Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat Immunol. 2001, 2: 698-704. 10.1038/90633CrossRefPubMed

45.

Banerjee SS, Feinberg MW, Watanabe M, Gray S, Haspel RL, Denkinger DJ, Kawahara R, Hauner H, Jain MK: The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem. 2003, 278: 2581-2584. 10.1074/jbc.M210859200CrossRefPubMed

46.

SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA, García-Cardeña G, Jain MK: KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004, 199: 1305-1315. 10.1084/jem.20031132PubMedCentralCrossRefPubMed

47.

Wu J, Lingrel JB: KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 2004, 23: 8088-8096. 10.1038/sj.onc.1207996CrossRefPubMed

48.

Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH, Chung TK, Lo KW, Yim SF, Yu MM, Ngan HY, Wong YF: Transcriptional repression of WEE1 by Krüppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene. 2005, 24: 3875-3885. 10.1038/sj.onc.1208546CrossRefPubMed

49.

Wick MJ, Blaine S, Van Putten V, Saavedra M, Nemenoff RA: Lung Krüppel-like factor (LKLF) is a transcriptional activator of the cytosolic phospholipase A2 alpha promoter. Biochem J. 2005, 387: 239-246. 10.1042/BJ20041458PubMedCentralCrossRefPubMed

50.

Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, Mukherjee P, Mukhopadhyay D, Jain MK: Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Krüppel-like factor KLF2. J Biol Chem. 2005, 280: 28848-28851. 10.1074/jbc.C500200200CrossRefPubMed

51.

Lomberk G, Urrutia R: The family feud: turning off Sp1 by Sp1-like KLF proteins. Biochem J. 2005, 392: 1-11. 10.1042/BJ20051234PubMedCentralCrossRefPubMed

52.

Maruyama I, Maruyama Y, Nakajima T, Kitajima I, Osame M, Zhao JQ, Chen IS, Nakai S, Ikeda M, Yabu-uchi Y, Adachi M: Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem Biophys Res Commun. 1993, 195: 1264-1271. 10.1006/bbrc.1993.2180CrossRefPubMed

Title: Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells
Authors: Daisuke Uchida
Tomitaro Onoue
Nasima-Mila Begum
Nobuyuki Kuribayashi
Yoshifumi Tomizuka
Tetsuya Tamatani
Hirokazu Nagai
Youji Miyamoto
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-8-62

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients

Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models

Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors

GSK3β N-terminus binding to p53 promotes its acetylation

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer